Plecanatide

What is Plecanatide?

Plecanatide (brand name TRULANCE, development code SP-304) is a 16-amino-acid synthetic peptide analogue of human uroguanylin that acts as an agonist of the guanylate cyclase-C (GC-C) receptor on intestinal epithelial cells. It was approved by the FDA on January 19, 2017 for chronic idiopathic constipation (CIC) and on January 24, 2018 for irritable bowel syndrome with constipation (IBS-C).

Structure and Origin

Where linaclotide is biomimetic of bacterial STa enterotoxin, plecanatide is biomimetic of uroguanylin, a natural human gut peptide that regulates intestinal fluid secretion under physiologic conditions. The endogenous origin gives plecanatide a pharmacologically distinct profile despite acting at the same receptor.

Sequence: NDDCELCVNVACTGCL (16 AA), with three intramolecular disulfide bonds. The single residue difference at position 3 (aspartic acid in plecanatide vs glutamic acid in linaclotide) confers pH-dependent GC-C affinity — plecanatide binds and activates GC-C more strongly in the slightly acidic pH of the proximal small intestine and less strongly as luminal pH rises distally.

Mechanism of Action

The downstream cascade is identical to linaclotide:

• Plecanatide binds GC-C on the apical (luminal) surface of intestinal enterocytes
• Intracellular cGMP rises
• CFTR chloride channels open via PKG II
• Chloride and bicarbonate secretion increases
• Fluid follows osmotically; stool softens; transit accelerates
• Submucosal sensory neuron signaling is modulated, reducing visceral pain

The clinical hypothesis behind plecanatide's pH dependence is that the proximal small intestine (acidic pH ~6) is the primary site of efficacy, while the distal small intestine and colon (more neutral) experience less GC-C activation, theoretically reducing the diarrhea-driven dose-limiting toxicity. In practice, head-to-head data are limited; both drugs are clinically effective, with similar efficacy magnitudes and slightly different tolerability profiles.

Clinical Evidence

Phase 3 CIC (Am J Gastroenterol 2017):

• 1,346 patients with CIC, 12 weeks of plecanatide 3 mg or 6 mg vs placebo
• FDA durable overall CSBM responder rate: 21.0% (3 mg) and 19.5% (6 mg) vs 10.2% placebo (p<0.001)

Phase 3 IBS-C (Am J Gastroenterol 2018):

• Two pivotal trials, ~2,200 patients with IBS-C
• Composite endpoint (≥30% reduction in abdominal pain + ≥1 CSBM increase, ≥6 of 12 weeks): 30% plecanatide 3 mg vs 17.8% placebo (p<0.001)

Approval History

• January 19, 2017 — FDA approval for CIC in adults
• January 24, 2018 — FDA approval for IBS-C in adults

Place in Therapy

Plecanatide is approved for adults with CIC or IBS-C and competes directly with linaclotide. Choice between the two often comes down to:

• Insurance formulary access
• Tolerability profile — some patients find plecanatide milder
• Once-daily dosing is the same for both
• Single dose strength — plecanatide is dosed at 3 mg once daily for both indications, whereas linaclotide has multiple dose strengths for different indications

Plecanatide is contraindicated in pediatric patients <6 years and not approved in pediatrics generally.

Safety Profile

The most common adverse event is diarrhea (~5%, vs ~16–20% with linaclotide in some comparative analyses, though direct head-to-head trials are limited). Like linaclotide, plecanatide has minimal systemic absorption and most adverse events are gut-localized.

Distinction from Linaclotide

Both drugs are clinically effective for chronic constipation and IBS-C; preference is often institutional or insurance-driven.